These data indicate the role of RUNX1 as a tumor suppressor in LR-MDS and suggest a functional impact of RUNX1 mutations, direct or indirect, in eliminating a biological anticancer barrier against accelerated progression in LR-MDS patients. Here, RUNX1 is linked to neoplasm.